NCT02546167: Phase 1 - CART-BCMA Cells for Multiple Myeloma
- Completed
- Dec 9, 2015
- 1 min read
Updated: Apr 26, 2022
NCT02546167: Phase 1 - CART-BCMA Cells for Multiple Myeloma
Open-label, single-center, pilot study to assess the safety and feasibility of infusion of autologous T cells expressing BCMA (B-cell maturation antigen)-specific chimeric antigen receptors with tandem TCR and 4-1BB costimulatory domains (referred to as CART-BCMA ) in adult patients with multiple myeloma (MM). CART-BCMA cells will be given as a split dose intravenous infusion over 3 days. The duration of active intervention and monitoring is approximately 2 years.
Sponsor: University of Pennsylvania
ClinicalTrials.gov Identifier: NCT02546167
Pilot Study Of Redirected Autologous T Cells Engineered To Contain an Anti-BCMA scFv Coupled To TCRζ And 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory Multiple Myeloma
Click here for details on Clinicaltrials.gov
autologous anti-BCMA-CAR-TCRz/4-1BB-expressing T lymphocytes CART-BCMA
autologous BCMA 4-1BBz CAR T cells CART-BCMA
autologous BCMA-specific CAR-TCRz/4-1BB-expressing T lymphocytes CART-BCMA
CART-BCMA cells
CART-BCMA
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma.
- PennsylvaniaL Abramson Cancer Center of the University of Pennsylvania Philadelphia
